Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6883224 | 0.85 | HTT (0.46) | MEN1KMT2ASMN1; SMN2TSHRLMNA | |
| SCHEMBL891381 | 0.83 | LMNA (0.42) | KMT2ASMN1; SMN2TSHRNPSR1LMNA | |
| SCHEMBL891352 | 0.81 | TRPM8 (0.40) | MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL17923426 | 0.78 | AAK1 (0.41) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| SCHEMBL891356 | 0.78 | TAS1R3 (0.40) | KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL891260 | 0.78 | AAK1 (0.40) | KMT2AALDH1A1 | |
| SCHEMBL9809965 | 0.77 | KIF11 (0.42) | PARP1NR3C2MEN1KMT2AALDH1A1 | |
| SCHEMBL18554580 | 0.75 | PARP1 (0.50) | PARP1IKBKBCA1CA2PARP10 | |
| SCHEMBL7063953 | 0.75 | DDX3X (0.36) | IKBKBMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL4838147 | 0.74 | CA1 (0.35) | MEN1KMT2ACA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671027-B2 | Use of GnRH agonists to support the luteal phase during infertility treatment | PREGLEM S.A. (CH) | 2010-03-02 | — | — | US | disclosed |
| US-7655658-B2 | Use of in the treatment of melanocortin receptor-associated disorders such as in treatment of anorexia, as a weight gain aid, for treatment of obesity | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1578427-B1 | USE OF GNRH AGONISTS TO SUPPORT THE LUTEAL PHASE DURING INFERTILITY TREATMENT | PREGLEM SA (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-20060069031-A1 | Use of gnrh agonists to support the luteal phase during infertility treatment | PREGLEM S.A. (CH) | 2006-03-30 | — | — | US | disclosed |
| EP-1578427-A1 | USE OF GNRH AGONISTS TO SUPPORT THE LUTEAL PHASE DURING INFERTILITY TREATMENT | Loumaye, Ernest (FR) | 2005-09-28 | — | — | EP | disclosed |
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2004058269-A9 | USE OF GNRH AGONISTS TO SUPPORT THE LUTEAL PHASE DURING INFERTILITY TREATMENT | LOUMAYE ERNEST (FR) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004058269-A1 | USE OF GNRH AGONISTS TO SUPPORT THE LUTEAL PHASE DURING INFERTILITY TREATMENT | LOUMAYE ERNEST (FR) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | MC1R, MC5R, MC4R | PARP1 2440/4885IKBKB 4061/4885F10 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.